Sight Sciences Q1 revenue $19.3M (+2% YoY); wins $34M jury verdict against Alcon

Sight Sciences, Inc.

2024-Q1 EPS reported -$0.33 revenue$19,265,000

Q1 2024 revenue $19.3M (+2% YoY); Surgical Glaucoma $18.3M (+5%), Dry Eye $1.0M (-32%).
Net loss $16.3M ($0.33/share) vs $17.1M ($0.35/share); gross margin 86% vs 84% prior year.
Jury found willful infringement by Alcon; awards $5.5M lost profits + $28.5M royalty for Hydrus Microstent.
Reaffirms FY2024 revenue guidance $81M-$85M (0-5% growth) and adjusted op ex $107M-$110M.
Cash burn reduced to $10.8M (incl. $3.2M debt restructuring costs) from $17.7M in Q1 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sight Sciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $19.3 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $19.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year. • Achieved total gross margin of 86% in the first quarter of 2024 compared to 84% in the same period in the

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-052094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.